They also demonstrated how a drug known to reduce inflammatory and neuropathic pain may also inhibit asthma symptoms in mice. Their paper is published in the May 18-22 online Early Edition of the Proceedings of the National Academy of Sciences.
There has been a dramatic increase in the number of asthma cases reported in recent decades. Scientists know that asthma involves an immune response to inhaled allergens that results in inflammation, mucus secretion and bronchial constriction. But limitations of existing treatments aimed at the immune system suggest that additional physiological mechanisms may be involved in asthmatic inflammation.
The new study tracks the role of the ion channel protein TRPA1. While the exact function of TRPA1 in the airway inflammation of asthma is not completely understood, scientists do know from previous research that this ion channel protein is a sensor for chemical irritants such as cigarette smoke and certain chemicals that also trigger asthma. TRPA1 is found in airway nerves that mediate pain and irritation and trigger coughing and sneezing.
The researchers found that mice with no TRPA1 showed fewer signs of asthma. According to the paper's lead author, Sven-Eric Jordt, Ph.D., assistant professor of pharmacology at Yale School of Medicine, "When compared to normal mice, those lacking the gene for TRPA1 had greatly diminished inflammation, airway mucus and bronchoconstriction."
Furthermore, when the Yale-Hydra team administered a pharmacological agent, HC-030031, that is known to inhibit pain related to TRPA1, to mice with asthma, their symptoms were diminished. "Blocking TRPA1 may prevent the infiltration of the lung by the inflammatory cells responsible for asthma symptoms such as wheezing and mucus overproduction," Jordt explained.
The pharmacological agent observed in this study to diminish asthmatic symptoms in mice was identified by Hydra Biosciences. Yale's Sven-Eric Jordt serves on Hydra's scientific advisory board and receives consulting fees from Hydra. Several other members on the research team are employees of Hydra Biosciences and have a financial interest in the potential development of HC-030031 as a pharmacological treatment.
In addition to Jordt, the team included Ana I. Caceres, Marian Brackmann, Maxwell D. Elia, Bret F. Bessac, Robert J. Homer and Lauren Cohn of Yale; Donato del Camino, Marc D'Amours, JoAnn S. Witek, Christopher M. Fanger, Jayhong A. Chong, Neil J. Hayward and Magdalene M. Moran (corresponding author) of Hydra Biosciences; and Xiaozhu Huang of University of California, San Francisco.
This research was funded by grants from the American Asthma Foundation and the National Institute of Environmental Health Sciences.
Helen Dodson | EurekAlert!
Cancer diagnosis: no more needles?
25.05.2018 | Christian-Albrechts-Universität zu Kiel
Less is more? Gene switch for healthy aging found
25.05.2018 | Leibniz-Institut für Alternsforschung - Fritz-Lipmann-Institut e.V. (FLI)
The more electronics steer, accelerate and brake cars, the more important it is to protect them against cyber-attacks. That is why 15 partners from industry and academia will work together over the next three years on new approaches to IT security in self-driving cars. The joint project goes by the name Security For Connected, Autonomous Cars (SecForCARs) and has funding of €7.2 million from the German Federal Ministry of Education and Research. Infineon is leading the project.
Vehicles already offer diverse communication interfaces and more and more automated functions, such as distance and lane-keeping assist systems. At the same...
A research team led by physicists at the Technical University of Munich (TUM) has developed molecular nanoswitches that can be toggled between two structurally different states using an applied voltage. They can serve as the basis for a pioneering class of devices that could replace silicon-based components with organic molecules.
The development of new electronic technologies drives the incessant reduction of functional component sizes. In the context of an international collaborative...
At the LASYS 2018, from June 5th to 7th, the Laser Zentrum Hannover e.V. (LZH) will be showcasing processes for the laser material processing of tomorrow in hall 4 at stand 4E75. With blown bomb shells the LZH will present first results of a research project on civil security.
At this year's LASYS, the LZH will exhibit light-based processes such as cutting, welding, ablation and structuring as well as additive manufacturing for...
There are videos on the internet that can make one marvel at technology. For example, a smartphone is casually bent around the arm or a thin-film display is rolled in all directions and with almost every diameter. From the user's point of view, this looks fantastic. From a professional point of view, however, the question arises: Is that already possible?
At Display Week 2018, scientists from the Fraunhofer Institute for Applied Polymer Research IAP will be demonstrating today’s technological possibilities and...
So-called quantum many-body scars allow quantum systems to stay out of equilibrium much longer, explaining experiment | Study published in Nature Physics
Recently, researchers from Harvard and MIT succeeded in trapping a record 53 atoms and individually controlling their quantum state, realizing what is called a...
25.05.2018 | Event News
02.05.2018 | Event News
13.04.2018 | Event News
25.05.2018 | Event News
25.05.2018 | Machine Engineering
25.05.2018 | Life Sciences